GlassScriptPhysician profile
Alexandre Elias Malek
NPI 1184122731
$4,764.32
in general payments reported to CMS, 2019-2025
17 companies · $1,356 in 2025
The $1,356 reported for 2025 was more than what 82% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $1,212 · 2023: $1,015 · 2024: $987 · 2025: $1,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,225 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,224.66 |
| Education | $133.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,194.95 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $573.47 | 2021-2025 | Zerbaxa, Dificid, Recarbrio |
| Shionogi INC | $550.67 | 2022-2025 | Fetroja |
| Viiv Healthcare Company | $502.86 | 2022-2025 | Cabenuva, Dovato |
| Astellas Pharma US INC | $493.51 | 2022-2025 | Cresemba |
| Paratek Pharmaceuticals, INC. | $395.23 | 2021-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $286.39 | 2022-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Insmed, INC. | $257.55 | 2022-2025 | Arikayce, Brinsupri |
| Gilead Sciences, INC. | $246.36 | 2022-2025 | Biktarvy, Sunlenca, Veklury |
| La Jolla Pharmaceutical Company | $63.39 | 2024-2025 | Xacduro, Zevtera |
| Invivyd INC | $53.07 | 2025 | Pemgarda |
| Takeda Pharmaceuticals U.S.A., INC. | $34.39 | 2024-2025 | Glassia |
| Theratechnologies INC. | $26.84 | 2023 | Egrifta, Trogarzo |
| Biomerieux INC | $25.00 | 2025 | Filmarray Torch Module |
| Zogenix INC. | $23.13 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $20.26 | 2022 | |
| Aimmune Therapeutics, INC. | $17.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandre Malek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.